These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32497987)

  • 1. The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer.
    van Barele M; Heemskerk-Gerritsen BAM; van Doorn HC; Schmidt MK; Hooning MJ; Jager A
    Breast; 2020 Aug; 52():102-109. PubMed ID: 32497987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
    Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients.
    Jeon SJ; Lee JI; Jeon MJ; Lee M
    Medicine (Baltimore); 2016 Apr; 95(14):e3301. PubMed ID: 27057900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients.
    Poikonen P; Saarto T; Elomaa I; Joensuu H; Blomqvist C
    Eur J Cancer; 2000 Jan; 36(1):43-8. PubMed ID: 10741293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
    Park IH; Han HS; Lee H; Lee KS; Kang HS; Lee S; Kim SW; Jung S; Ro J
    Ann Oncol; 2012 Sep; 23(9):2283-2289. PubMed ID: 22377562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
    Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors.
    Raghavendra A; Sinha AK; Valle-Goffin J; Shen Y; Tripathy D; Barcenas CH
    Clin Breast Cancer; 2018 Feb; 18(1):e7-e13. PubMed ID: 29239836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients.
    Vanhuyse M; Fournier C; Bonneterre J
    Ann Oncol; 2005 Aug; 16(8):1283-8. PubMed ID: 15870085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
    Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
    Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
    Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
    Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.
    Minisini AM; Menis J; Valent F; Andreetta C; Alessi B; Pascoletti G; Piga A; Fasola G; Puglisi F
    Anticancer Drugs; 2009 Jul; 20(6):503-7. PubMed ID: 19339872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG; Malmgren JA; Atwood M
    Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.